Forum Financial Management LP Grows Holdings in Sanofi (NASDAQ:SNY)

Forum Financial Management LP raised its stake in shares of Sanofi (NASDAQ:SNY - Free Report) by 76.1% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 66,827 shares of the company's stock after buying an additional 28,879 shares during the quarter. Forum Financial Management LP's holdings in Sanofi were worth $3,223,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of SNY. Arkadios Wealth Advisors raised its stake in shares of Sanofi by 19.0% during the fourth quarter. Arkadios Wealth Advisors now owns 4,709 shares of the company's stock worth $227,000 after acquiring an additional 751 shares in the last quarter. Kentucky Trust Co purchased a new position in Sanofi in the 4th quarter worth approximately $436,000. Van ECK Associates Corp increased its stake in Sanofi by 18.1% in the 4th quarter. Van ECK Associates Corp now owns 662,762 shares of the company's stock worth $31,965,000 after purchasing an additional 101,726 shares during the period. Sound Income Strategies LLC increased its stake in Sanofi by 156,520.9% in the 4th quarter. Sound Income Strategies LLC now owns 67,347 shares of the company's stock worth $3,248,000 after purchasing an additional 67,304 shares during the period. Finally, Allspring Global Investments Holdings LLC increased its stake in Sanofi by 128.0% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 115,330 shares of the company's stock worth $5,558,000 after purchasing an additional 64,747 shares during the period. 14.04% of the stock is currently owned by institutional investors.

Sanofi Stock Performance

Shares of NASDAQ:SNY traded up $0.41 during midday trading on Tuesday, reaching $52.39. 1,925,564 shares of the company's stock traded hands, compared to its average volume of 2,376,691. The company has a market cap of $132.35 billion, a price-to-earnings ratio of 21.04, a P/E/G ratio of 1.01 and a beta of 0.55. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. Sanofi has a one year low of $45.80 and a one year high of $60.12. The stock has a 50 day moving average of $52.65 and a 200 day moving average of $51.89.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its earnings results on Thursday, April 24th. The company reported $0.94 earnings per share for the quarter, beating analysts' consensus estimates of $0.90 by $0.04. The company had revenue of $10.41 billion for the quarter, compared to the consensus estimate of $9.79 billion. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Sanofi's revenue was down 11.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.78 earnings per share. As a group, equities research analysts anticipate that Sanofi will post 4.36 EPS for the current fiscal year.

Sanofi Increases Dividend

The business also recently declared an annual dividend, which will be paid on Thursday, June 12th. Shareholders of record on Friday, May 9th will be given a $2.0369 dividend. This is a boost from Sanofi's previous annual dividend of $1.48. The ex-dividend date is Friday, May 9th. This represents a yield of 3.1%. Sanofi's dividend payout ratio is presently 57.14%.

Analysts Set New Price Targets

SNY has been the topic of a number of analyst reports. Hsbc Global Res raised Sanofi to a "strong-buy" rating in a research note on Monday, April 28th. Sanford C. Bernstein raised Sanofi to a "strong-buy" rating in a research note on Thursday, January 30th. The Goldman Sachs Group started coverage on Sanofi in a research note on Friday, March 21st. They set a "neutral" rating and a $65.00 target price on the stock. Deutsche Bank Aktiengesellschaft raised Sanofi from a "sell" rating to a "hold" rating in a research note on Thursday, January 30th. Finally, BNP Paribas started coverage on Sanofi in a research note on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 price target on the stock. Three investment analysts have rated the stock with a hold rating, two have issued a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $63.33.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.